Login Register Cart 0
Generic placeholder image

Drug Metabolism and Bioanalysis Letters

Editor-in-Chief

ISSN (Print): 2949-6810
ISSN (Online): 2949-6829

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Research Article

Effect of Saccharolactone on CYP-mediated Metabolism of Xenobiotics

Author(s): Dayanidhi Behera*, Pankaj Jain, Vishwanath Kurawattimath and Nagaraj Gowda

Volume 16, Issue 2, 2023

Published on: 07 September, 2023

Page: [121 - 132] Pages: 12

DOI: 10.2174/2949681016666230823094423

Price: $65

conference banner
Abstract

Background: Saccharolactone is used as a β-glucuronidase inhibitor in in vitro microsomal and recombinant uridine diphosphoglucuronosyl transferases (rUGTs) incubations to enhance glucuronide pathway and, thereby, formation of glucuronide metabolites. We investigated its effect on CYP mediated metabolism of drugs (compound-174, phenacetin and quinidine) using human liver microsomes (HLM) supplemented with Phase-1 and Phase-2 co-factors.

Methods: Compounds were incubated in HLM supplemented with co-factors to assess Phase-1 (NADPH) and Phase-2 (NADPH, alamethicin, saccharolactone and UDPGA) metabolism. CYP phenotype assay for compound-174 was conducted in HLM (± 1-ABT) and human recombinant CYP isoforms. CYP inhibition profile of saccharolactone was also generated in HLM.

Results: The metabolism of compound-174, phenacetin and quinidine in HLM significantly decreased in reactions containing additional components like alamethicin, saccharolactone and UDPGA and indicated that the addition of saccharolactone inhibited the metabolism. Phenacetin and quinidine are known substrates of CYP1A2 and CYP3A4 isoforms. The metabolism of compound- 174 was significantly inhibited in the presence of 1-ABT in HLM, and CYP3A4 and CYP2C8 isoforms were found to be the predominant isoforms responsible for its metabolism. Further evaluation of CYP inhibition in HLM indicated saccharolactone to be a strong inhibitor of CYP1A2, 2D6, 3A4 and 2C8 isoforms with IC50 values of less than 4 mM.

Conclusion: The findings indicated that saccharolactone being a strong inhibitor of CYP1A2, 2D6, 3A4 and 2C8 isoforms (IC50 < 4 mM), resulted in significant inhibition of the metabolism of compound-174, phenacetin and quinidine in HLM and caution should be exercised in using it with proper titration of the concentrations.

Keywords: Cytochrome P450 (CYP), UDP-glucuronosyltransferases (UGT), metabolism, human liver microsomes, saccharolactone, β-glucuronidase, CYP inhibition.

« Previous Next »
Graphical Abstract

[1]
Clarke, S.E.; Jones, B.C. Human cytochromes P450 and their role in metabolism-based drug-drug interactions. In: Drug-drug interactions; 2nd ed.; Informa Healthcare Inc: New York, 2008; p. 53-54.
[2]
Wang, J.F.; Chou, K.C. Molecular modeling of cytochrome P450 and drug metabolism. Curr. Drug Metab., 2010, 11(4), 342-346.
[http://dx.doi.org/10.2174/138920010791514180] [PMID: 20446905]
[3]
Behera, D.; Pattem, R.; Kumar, M.S.S.; Gudi, G.S. Utility of a column-switching LC/MS/MS method in cytochrome P450 inhibition assays using human liver microsomes. Drug Metabol. Drug Interact., 2013, 28(3), 177-185.
[http://dx.doi.org/10.1515/dmdi-2013-0004] [PMID: 23729559]
[4]
Miners, J.O.; Mackenzie, P.I. Drug glucuronidation in humans. Pharmacol. Ther., 1991, 51(3), 347-369.
[http://dx.doi.org/10.1016/0163-7258(91)90065-T] [PMID: 1792239]
[5]
Miners, J.O.; McKinnon, R.A.; Mackenzie, P.I. Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance. Toxicology, 2002, 181-182, 453-456.
[http://dx.doi.org/10.1016/S0300-483X(02)00449-3] [PMID: 12505351]
[6]
Mulder, G.J. Glucuronidation and its role in regulation of biological activity of drugs. Annu. Rev. Pharmacol. Toxicol., 1992, 32(1), 25-49.
[http://dx.doi.org/10.1146/annurev.pa.32.040192.000325] [PMID: 1605568]
[7]
Oleson, L.; Court, M.H. Effect of the β-glucuronidase inhibitor saccharolactone on glucuronidation by human tissue microsomes and recombinant UDP-glucuronosyltransferases. J. Pharm. Pharmacol., 2010, 60(9), 1175-1182.
[http://dx.doi.org/10.1211/jpp.60.9.0009] [PMID: 18718121]
[8]
Fisher, M.B.; Campanale, K.; Ackermann, B.L.; VandenBranden, M.; Wrighton, S.A. In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metab. Dispos., 2000, 28(5), 560-566.
[PMID: 10772635]
[9]
Soars, M.G.; Ring, B.J.; Wrighton, S.A. The effect of incubation conditions on the enzyme kinetics of udp-glucuronosyltransferases. Drug Metab. Dispos., 2003, 31(6), 762-767.
[http://dx.doi.org/10.1124/dmd.31.6.762] [PMID: 12756209]
[10]
Marsh, C.A.; Alexander, F.; Levvy, G.A. Glucuronide decomposition in the digestive tract. Nature, 1952, 170(4317), 163-164.
[http://dx.doi.org/10.1038/170163a0] [PMID: 14957059]
[11]
Levvy, G.; Marsh, C.A. β-glucuronidase. In: The Enzymes; Myrbäck, K., Ed.; Academic Press: New York, 1960.
[12]
Wakabayashi, M. β-Glucuronidases in metabolic hydrolysis. In: Metabolic Conjucation and Metabolic Hydrolysis; Fishman, W., Ed.; Academic Press: New York, 1970.
[13]
Swank, R.T.; Pfister, K.; Miller, D.; Chapman, V. The egasyn gene affects the processing of oligosaccharides of lysosomal β -glucuronidase in liver. Biochem. J., 1986, 240(2), 445-454.
[http://dx.doi.org/10.1042/bj2400445] [PMID: 3101673]
[14]
Brunelle, F.M.; Verbeeck, R.K. Glucuronidation of diflunisal by rat liver microsomes. Biochem. Pharmacol., 1993, 46(11), 1953-1958.
[http://dx.doi.org/10.1016/0006-2952(93)90636-B] [PMID: 8267644]
[15]
Argikar, U.A. Saccharolactone: The history, the myth, and the practice. Curr. Drug Metab., 2018, 19(4), 304-309.
[http://dx.doi.org/10.2174/1389200219666171229232007] [PMID: 29298647]
[16]
Patel, V. Novel inhibitors of MAP4K1. Patent WO 2018/215668Al, 2018.
[17]
Davies, B.; Morris, T. Physiological parameters in laboratory animals and humans. Pharm. Res., 1993, 10(7), 1093-1095.
[http://dx.doi.org/10.1023/A:1018943613122] [PMID: 8378254]
[18]
Iwatsubo, T.; Suzuki, H.; Sugiyama, Y. Prediction of species differences (rats, dogs, humans) in the in vivo metabolic clearance of YM796 by the liver from in vitro data. J. Pharmacol. Exp. Ther., 1997, 283(2), 462-469.
[PMID: 9353358]
[19]
Kilford, P.J.; Stringer, R.; Sohal, B.; Houston, J.B.; Galetin, A. Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransf-erase cofactors in alamethicin-activated human liver microsomes. Drug Metab. Dispos., 2009, 37(1), 82-89.
[http://dx.doi.org/10.1124/dmd.108.023853] [PMID: 18832476]
[20]
Harper, T.W.; Brassil, P.J. Reaction phenotyping: Current industry efforts to identify enzymes responsible for metabolizing drug candidates. AAPS J., 2008, 10(1), 200-207.
[http://dx.doi.org/10.1208/s12248-008-9019-6] [PMID: 18446520]
[21]
Chen, Y.; Liu, L.; Nguyen, K.; Fretland, A.J. Utility of intersystem extrapolation factors in early reaction phenotyping and the quantitative extrapolation of human liver microsomal intrinsic clearance using recombinant cytochromes P450. Drug Metab. Dispos., 2011, 39(3), 373-382.
[http://dx.doi.org/10.1124/dmd.110.035147] [PMID: 21148079]
[22]
Yang, X.; Atkinson, K.; Di, L. Novel Cytochrome P450 reaction phenotyping for low-clearance compounds using the hepatocyte relay method. Drug Metab. Dispos., 2016, 44(3), 460-465.
[http://dx.doi.org/10.1124/dmd.115.067876] [PMID: 26700955]

Rights & Permissions Print Cite
Article Metrics
27
2
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy